BRPI0812795A2 - Domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso do antagonista de tnfr1, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, composição farmacêutica, polipeptídeo, e, proteína de fusão. - Google Patents

Domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso do antagonista de tnfr1, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, composição farmacêutica, polipeptídeo, e, proteína de fusão.

Info

Publication number: BRPI0812795A2
Authority: BR; Brazil
Prior art keywords: polypeus; fetus; antagonist; tnfalfa; propellane
Prior art date: 2007-06-06

Application number

BRPI0812795-6A2A

Other languages

English (en)

Inventor

Laurent Jespers

Malgorzata Pupecka

Ian Tomlinson

Carolyn Enever

Original Assignee

Domantis Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-06

Filing date

2008-06-04

Publication date

2014-12-02

2007-12-13 Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en

2008-06-04 Application filed by Domantis Ltd filed Critical Domantis Ltd

2014-12-02 Publication of BRPI0812795A2 publication Critical patent/BRPI0812795A2/pt

2019-12-03 Publication of BRPI0812795B1 publication Critical patent/BRPI0812795B1/pt

2020-01-28 Publication of BRPI0812795B8 publication Critical patent/BRPI0812795B8/pt

2021-05-25 Publication of BRPI0812795C1 publication Critical patent/BRPI0812795C1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Dispersion Chemistry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)

BRPI0812795A 2007-06-06 2008-06-04 domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica BRPI0812795C1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93363207P	2007-06-06	2007-06-06
GBGB0724331.4A GB0724331D0 (en)	2007-12-13	2007-12-13	Compositions for pulmonary delivery
PCT/GB2008/050405 WO2008149148A2 (en)	2007-06-06	2008-06-04	Polypeptides, antibody variable domains and antagonists

Publications (4)

Publication Number	Publication Date
BRPI0812795A2 true BRPI0812795A2 (pt)	2014-12-02
BRPI0812795B1 BRPI0812795B1 (pt)	2019-12-03
BRPI0812795B8 BRPI0812795B8 (pt)	2020-01-28
BRPI0812795C1 BRPI0812795C1 (pt)	2021-05-25

Family

ID=39791116

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BRPI0812268A BRPI0812268A2 (pt)	2007-06-06	2008-06-04	domínio variável simples de imunoglobulina tipo 1 de receptor anti-interleucina-1, antagonista tipo 1 do receptor anti-interleucina-1, uso do mesmo, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, proteína de fusão, e, ácido nucleico isolado ou recombinante.
BRPI0812795A BRPI0812795C1 (pt)	2007-06-06	2008-06-04	domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso de um domínio ou antagonista de tnfr1, ácido nucleico recombinante, vetor, célula hospedeira, e, composição farmacêutica
BRPI0813899A BRPI0813899A2 (pt)	2007-06-06	2008-06-04	domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente a protease, uso do antagonista vegf ou domínio variável, método para a dispensação oral ou dispensação de um medicamento ao trato de gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pumonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812268A BRPI0812268A2 (pt)	2007-06-06	2008-06-04	domínio variável simples de imunoglobulina tipo 1 de receptor anti-interleucina-1, antagonista tipo 1 do receptor anti-interleucina-1, uso do mesmo, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, proteína de fusão, e, ácido nucleico isolado ou recombinante.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813899A BRPI0813899A2 (pt)	2007-06-06	2008-06-04	domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente a protease, uso do antagonista vegf ou domínio variável, método para a dispensação oral ou dispensação de um medicamento ao trato de gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pumonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão

Country Status (31)

Country	Link
US (5)	US20100247515A1 (pt)
EP (5)	EP2164867A2 (pt)
JP (3)	JP2010530364A (pt)
KR (4)	KR20100018040A (pt)
CN (4)	CN101883788A (pt)
AR (3)	AR066848A1 (pt)
AU (4)	AU2008259590A1 (pt)
BR (3)	BRPI0812268A2 (pt)
CA (6)	CA2688433A1 (pt)
CL (3)	CL2008001676A1 (pt)
CO (2)	CO6251322A2 (pt)
CR (2)	CR11195A (pt)
CY (1)	CY1116762T1 (pt)
DK (1)	DK2162467T3 (pt)
DO (1)	DOP2009000268A (pt)
EA (5)	EA200901494A1 (pt)
ES (1)	ES2546943T3 (pt)
HR (1)	HRP20151024T1 (pt)
HU (1)	HUE025899T2 (pt)
IL (2)	IL201398A0 (pt)
MA (2)	MA31403B1 (pt)
MX (4)	MX2009013137A (pt)
NZ (1)	NZ581372A (pt)
PE (3)	PE20090323A1 (pt)
PL (1)	PL2162467T3 (pt)
PT (1)	PT2162467E (pt)
SG (2)	SG182151A1 (pt)
SI (1)	SI2162467T1 (pt)
TW (6)	TW200907128A (pt)
WO (3)	WO2008149150A2 (pt)
ZA (1)	ZA200908470B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP3613767A1 (en)	2005-05-18	2020-02-26	Ablynx N.V.	Improved nanobodiestm against tumor cecrosis factor-alpha
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
MX2009013137A (es)	2007-06-06	2010-04-30	Domantis Ltd	Metodos para seleccionar polipeptidos resistentes a la proteasa.
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
JP2010528647A (ja) *	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2011506396A (ja) *	2007-12-13	2011-03-03	グラクソグループリミテッド	肺送達用組成物
EP2268668A1 (en)	2008-04-17	2011-01-05	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DK2307454T3 (en)	2008-06-25	2017-04-24	Esbatech Alcon Biomed Res Unit	Stable and soluble antibodies that inhibit VEGF
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
KR20110091777A (ko) *	2008-11-26	2011-08-12	글락소 그룹 리미티드	폴리펩티드, 항체 가변 도메인 및 길항제
WO2010081787A1 (en)	2009-01-14	2010-07-22	Domantis Limited	IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
PE20120001A1 (es)	2009-02-19	2012-02-12	Glaxo Group Ltd	Dominios variables simples anti-albumina de suero mejorados
EP2398825B1 (en)	2009-02-19	2017-10-25	Glaxo Group Limited	Single variable domain against serum albumin
CA2750477A1 (en) *	2009-02-19	2010-08-26	Stephen Duffield	Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
CA2753287A1 (en)	2009-02-24	2010-09-02	Glaxo Group Limited	Antigen-binding constructs
BR112012001681A2 (pt)	2009-07-16	2019-09-24	Graxo Group Ltd	domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
JP2012532619A (ja) *	2009-07-16	2012-12-20	グラクソグループリミテッド	Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011047215A1 (en) *	2009-10-14	2011-04-21	Aileron Therapeutics, Inc.	Improved peptidomimetic macrocycles
CA2777312A1 (en)	2009-10-27	2011-05-05	Inusha De Silva	Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
AU2011212442A1 (en)	2010-02-05	2012-08-09	Ablynx Nv	Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2571900A1 (en) *	2010-05-20	2013-03-27	Glaxo Group Limited	Improved anti-serum albumin binding variants
US9012609B2 (en) *	2010-08-13	2015-04-21	Glaxosmithkline Intellectual Property Development Limited	Anti-serum albumin binding variants
US20130230519A1 (en) *	2010-08-20	2013-09-05	Elena De Angelis	Anti-serum albumin binding variants
CN103249742B (zh) *	2010-09-16	2017-04-12	巴利奥医药股份公司	抗人肿瘤坏死因子1型受体抗体
EP2646467A2 (en)	2010-12-01	2013-10-09	Glaxo Group Limited	Improved anti-serum albumin binding single variable domains
WO2012104227A1 (en)	2011-02-02	2012-08-09	Glaxo Group Limited	Novel antigen binding proteins
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US10400029B2 (en)	2011-06-28	2019-09-03	Inhibrx, Lp	Serpin fusion polypeptides and methods of use thereof
KR20220003656A (ko)	2011-06-28	2022-01-10	인히브릭스, 인크.	세르핀 융합 폴리펩타이드 및 이의 이용 방법
EP2736925A2 (en) *	2011-07-27	2014-06-04	Glaxo Group Limited	Anti-vegf single variable domains fused to fc domains
TW201321405A (zh)	2011-08-17	2013-06-01	Glaxo Group Ltd	經修飾之蛋白質及肽
GB2497138A (en) *	2011-12-02	2013-06-05	Randox Lab Ltd	Biomarkers for stroke and stroke subtype diagnosis.
SMT202100621T1 (it)	2012-07-13	2022-01-10	Roche Glycart Ag	Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
RU2015128651A (ru)	2013-01-31	2017-03-06	Глаксо Груп Лимитед	Способ продуцирования белка
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41374A (fr) *	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3397276A4 (en)	2015-12-30	2019-12-18	Kodiak Sciences Inc.	ANTIBODIES AND CONJUGATES THEREOF
GB201617622D0 (en) *	2016-10-18	2016-11-30	VIB VZW and Universiteit Gent	Means and methods to treat inflammation
RU2625010C1 (ru) *	2016-11-10	2017-07-11	Илья Петрович Приколаб	Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
CA3039316A1 (en)	2016-11-28	2018-05-31	Chugai Seiyaku Kabushiki Kaisha	Ligand-binding molecule having adjustable ligand binding activity
US11168139B2 (en)	2016-11-28	2021-11-09	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding domain, and polypeptide including conveying section
UY37651A (es) *	2017-03-31	2018-10-31	Swedish Orphan Biovitrum Ab Publ	Polipéptido de unión al il-1r-i
JP7261232B2 (ja) *	2017-11-01	2023-04-19	アロジーンセラピューティクス，インコーポレイテッド	改変カスパーゼ－９ポリペプチドおよびその使用方法
TWI818934B (zh)	2017-11-28	2023-10-21	日商中外製藥股份有限公司	可調整配體結合活性的配體結合分子
WO2019107380A1 (ja)	2017-11-28	2019-06-06	中外製薬株式会社	抗原結合ドメインおよび運搬部分を含むポリペプチド
KR20200140817A (ko)	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	Il-6 항체 그리고 이의 융합 작제물 및 접합체
JP7414736B2 (ja)	2018-05-30	2024-01-16	中外製薬株式会社	アグリカン結合ドメインおよび運搬部分を含むポリペプチド
WO2019230866A1 (en) *	2018-05-30	2019-12-05	Chugai Seiyaku Kabushiki Kaisha	Polypeptide comprising il-1r1 binding domain and carrying moiety
EP3623798B1 (de) *	2018-09-13	2021-11-03	Euroimmun Medizinische Labordiagnostika AG	Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
EP3870331B1 (en) *	2018-10-25	2025-07-23	F. Hoffmann-La Roche AG	Modification of antibody fcrn binding
MX2021004774A (es)	2018-10-29	2021-08-24	Hoffmann La Roche	Formulacion de anticuerpos.
MY205459A (en)	2018-12-06	2024-10-22	Cytomx Therapeutics Inc	Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CN111454366B (zh) *	2019-01-21	2023-06-16	中国科学院深圳先进技术研究院	一种融合蛋白及其应用
CN113728233B (zh) *	2019-01-31	2024-09-13	积水医疗株式会社	用于生物样品中的游离aim的免疫分析方法和分析试剂盒
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
JP7473398B2 (ja) *	2020-05-28	2024-04-23	シスメックス株式会社	キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法
CN116847887A (zh) *	2020-08-27	2023-10-03	伊诺西治疗公司	治疗自身免疫性疾病和癌症的方法和组合物
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115181751A (zh) *	2021-04-02	2022-10-14	苏州博腾生物制药有限公司	靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) *	2022-03-04	2023-06-16	华南理工大学	一种具有血管内皮细胞保护功能的抗氧化五肽及其应用
CN115112704B (zh) *	2022-06-21	2025-07-15	中特检验集团有限公司	一种光热发电有机热载体热稳定性检测方法
AR129879A1 (es)	2022-07-08	2024-10-09	Novo Nordisk As	Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
WO2025049818A1 (en)	2023-08-29	2025-03-06	Enosi Therapeutics Corporation	Tnfr1 antagonists lacking agonist activity and uses thereof
CN119909772B (zh) *	2025-04-01	2025-06-20	安徽一帆新材料科技有限公司	用于净水的再生阴树脂及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
WO1989007142A1 (en)	1988-02-05	1989-08-10	Morrison Sherie L	Domain-modified constant region antibodies
DE768377T1 (de)	1988-09-02	1998-01-02	Dyax Corp	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ATE92107T1 (de)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en)	1989-09-07	1999-11-02	Alkermes, Inc.	Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
CA2097708A1 (en)	1990-12-06	1992-06-07	Stephen P. A. Fodor	Very large scale immobilized polymer synthesis
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US5702892A (en)	1995-05-09	1997-12-30	The United States Of America As Represented By The Department Of Health And Human Services	Phage-display of immunoglobulin heavy chain libraries
DK1143006T3 (da)	1995-08-18	2008-07-14	Morphosys Ip Gmbh	Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6258562B1 (en) *	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
DE69838521T2 (de)	1997-07-07	2008-05-21	Medical Research Council	Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
EP1078051B1 (en)	1998-05-13	2007-12-12	Domantis Limited	Phage-display system for the selection of correctly folded proteins
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
JP2003523742A (ja)	2000-02-03	2003-08-12	ドマンティスリミテッド	コンビナトリアルタンパク質ドメイン
WO2001058953A2 (en)	2000-02-11	2001-08-16	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7115415B2 (en) *	2000-09-15	2006-10-03	Genentech, Inc.	PRO9821 nucleic acids
TWI327600B (en)	2000-11-28	2010-07-21	Medimmune Llc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
DE60237282D1 (de)	2001-06-28	2010-09-23	Domantis Ltd	Doppelspezifischer ligand und dessen verwendung
US20060073141A1 (en) *	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
GB0118689D0 (en) *	2001-08-01	2001-09-19	Psimedica Ltd	Pharmaceutical formulation
AU2003210806A1 (en)	2002-03-05	2003-09-22	Eli Lilly And Company	Heterologous g-csf fusion proteins
US20060002935A1 (en) *	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en) *	2002-06-28	2005-12-07	Domantis Limited	Ligand
US7696320B2 (en) *	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN104178491B (zh)	2002-09-06	2018-07-03	安姆根有限公司	治疗性人抗-il-1r1单克隆抗体
WO2004022096A1 (en)	2002-09-06	2004-03-18	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
CA2511910A1 (en)	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20060104968A1 (en) *	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004220325B2 (en) *	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
CA2554089C (en)	2004-02-09	2013-10-22	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2172553A1 (en)	2004-03-24	2010-04-07	Domantis Limited	Gas1 universal leader
PT1802334E (pt) *	2004-10-21	2012-11-28	Genentech Inc	Método para tratamento de doenças neovasculares intraoculares
GB0521621D0 (en) *	2005-10-24	2005-11-30	Domantis Ltd	Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2588892A1 (en) *	2004-12-02	2006-06-08	Dormantis Limited	Anti-il-1r1 single domain antibodies and therapeutic uses
CN101466734A (zh) *	2005-12-01	2009-06-24	杜门蒂斯有限公司	与白细胞介素-1受体1型结合的竞争性域抗体形式
JP2009519011A (ja) *	2005-12-01	2009-05-14	ドマンティスリミテッド	インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
ES2766770T3 (es)	2006-08-10	2020-06-15	Roy C Levitt	Anakinra para uso en el tratamiento del síndrome de bronquiolitis obliterante
US20100129354A1 (en) *	2006-10-27	2010-05-27	Ablynx N.V.	Intranasal delivery of polypeptides and proteins
MX2009013137A (es)	2007-06-06	2010-04-30	Domantis Ltd	Metodos para seleccionar polipeptidos resistentes a la proteasa.
JP2010528647A (ja)	2007-06-06	2010-08-26	ドマンティスリミテッド	ポリペプチド、抗体可変ドメインおよびアンタゴニスト

2008
- 2008-06-03 MX MX2009013137A patent/MX2009013137A/es not_active Application Discontinuation
- 2008-06-03 CA CA002688433A patent/CA2688433A1/en not_active Abandoned
- 2008-06-03 CA CA002683791A patent/CA2683791A1/en not_active Abandoned
- 2008-06-03 CA CA002688434A patent/CA2688434A1/en not_active Abandoned
- 2008-06-03 EA EA200901494A patent/EA200901494A1/ru unknown
- 2008-06-03 KR KR1020107000188A patent/KR20100018040A/ko not_active Withdrawn
- 2008-06-03 AU AU2008259590A patent/AU2008259590A1/en not_active Abandoned
- 2008-06-04 AR ARP080102363A patent/AR066848A1/es not_active Application Discontinuation
- 2008-06-04 AR ARP080102365A patent/AR066850A1/es not_active Application Discontinuation
- 2008-06-04 EA EA200901491A patent/EA018129B1/ru not_active IP Right Cessation
- 2008-06-04 JP JP2010510888A patent/JP2010530364A/ja active Pending
- 2008-06-04 AU AU2008259515A patent/AU2008259515A1/en not_active Abandoned
- 2008-06-04 ES ES08750800.8T patent/ES2546943T3/es active Active
- 2008-06-04 EP EP08750801A patent/EP2164867A2/en not_active Withdrawn
- 2008-06-04 MX MX2009013138A patent/MX2009013138A/es active IP Right Grant
- 2008-06-04 WO PCT/GB2008/050407 patent/WO2008149150A2/en not_active Ceased
- 2008-06-04 DK DK08750800.8T patent/DK2162467T3/en active
- 2008-06-04 EP EP13184209.8A patent/EP2746290B1/en active Active
- 2008-06-04 SG SG2012040275A patent/SG182151A1/en unknown
- 2008-06-04 EA EA200901495A patent/EA018723B1/ru not_active IP Right Cessation
- 2008-06-04 EP EP08750800.8A patent/EP2162467B1/en active Active
- 2008-06-04 CN CN2008801020043A patent/CN101883788A/zh active Pending
- 2008-06-04 BR BRPI0812268A patent/BRPI0812268A2/pt not_active IP Right Cessation
- 2008-06-04 SI SI200831508T patent/SI2162467T1/sl unknown
- 2008-06-04 AU AU2008259516A patent/AU2008259516A1/en not_active Abandoned
- 2008-06-04 CN CN201410440384.9A patent/CN104311663B/zh not_active Expired - Fee Related
- 2008-06-04 WO PCT/GB2008/050405 patent/WO2008149148A2/en not_active Ceased
- 2008-06-04 PT PT87508008T patent/PT2162467E/pt unknown
- 2008-06-04 CA CA002683823A patent/CA2683823A1/en not_active Abandoned
- 2008-06-04 US US12/663,506 patent/US20100247515A1/en not_active Abandoned
- 2008-06-04 BR BRPI0812795A patent/BRPI0812795C1/pt not_active IP Right Cessation
- 2008-06-04 AR ARP080102362A patent/AR066847A1/es unknown
- 2008-06-04 CN CN200880102207.2A patent/CN101778865B/zh not_active Expired - Fee Related
- 2008-06-04 CA CA002688456A patent/CA2688456A1/en not_active Abandoned
- 2008-06-04 KR KR1020107000212A patent/KR101604274B1/ko not_active Expired - Fee Related
- 2008-06-04 US US12/663,502 patent/US8398979B2/en not_active Expired - Fee Related
- 2008-06-04 KR KR1020107000213A patent/KR20100041746A/ko not_active Withdrawn
- 2008-06-04 HU HUE08750800A patent/HUE025899T2/en unknown
- 2008-06-04 NZ NZ581372A patent/NZ581372A/en not_active IP Right Cessation
- 2008-06-04 PE PE2008000944A patent/PE20090323A1/es not_active Application Discontinuation
- 2008-06-04 CA CA2688447A patent/CA2688447C/en active Active
- 2008-06-04 CN CN200880019060A patent/CN101802004A/zh active Pending
- 2008-06-04 KR KR1020107000223A patent/KR20100040841A/ko not_active Withdrawn
- 2008-06-04 MX MX2009012967A patent/MX2009012967A/es not_active Application Discontinuation
- 2008-06-04 WO PCT/GB2008/050406 patent/WO2008149149A2/en not_active Ceased
- 2008-06-04 AU AU2008259514A patent/AU2008259514B2/en not_active Ceased
- 2008-06-04 SG SG2012039541A patent/SG182141A1/en unknown
- 2008-06-04 EP EP13184211.4A patent/EP2746291B1/en active Active
- 2008-06-04 PE PE2008000943A patent/PE20090763A1/es not_active Application Discontinuation
- 2008-06-04 HR HRP20151024TT patent/HRP20151024T1/hr unknown
- 2008-06-04 JP JP2010510886A patent/JP5325211B2/ja not_active Expired - Fee Related
- 2008-06-04 BR BRPI0813899A patent/BRPI0813899A2/pt not_active IP Right Cessation
- 2008-06-04 PL PL08750800T patent/PL2162467T3/pl unknown
- 2008-06-04 EP EP08750802A patent/EP2162468A2/en not_active Withdrawn
- 2008-06-04 PE PE2008000940A patent/PE20090322A1/es not_active Application Discontinuation
- 2008-06-04 JP JP2010510887A patent/JP5444215B2/ja active Active
- 2008-06-04 EA EA200901300A patent/EA200901300A1/ru unknown
- 2008-06-04 MX MX2009013211A patent/MX2009013211A/es active IP Right Grant
- 2008-06-06 TW TW097121280A patent/TW200907128A/zh unknown
- 2008-06-06 TW TW097121301A patent/TW200918088A/zh unknown
- 2008-06-06 TW TW097121295A patent/TW200911832A/zh unknown
- 2008-06-06 TW TW097121296A patent/TW200902551A/zh unknown
- 2008-06-06 CL CL2008001676A patent/CL2008001676A1/es unknown
- 2008-06-06 TW TW097121265A patent/TW200911834A/zh unknown
- 2008-06-06 TW TW097121268A patent/TW200911831A/zh unknown
- 2008-06-06 CL CL2008001674A patent/CL2008001674A1/es unknown
- 2008-06-06 CL CL2008001673A patent/CL2008001673A1/es unknown
- 2008-11-26 US US12/323,632 patent/US20090148437A1/en not_active Abandoned
2009
- 2009-10-11 IL IL201398A patent/IL201398A0/en unknown
- 2009-11-04 US US13/130,656 patent/US20110256122A1/en not_active Abandoned
- 2009-11-04 EA EA201100546A patent/EA201100546A1/ru unknown
- 2009-11-18 IL IL202204A patent/IL202204A0/en unknown
- 2009-11-27 DO DO2009000268A patent/DOP2009000268A/es unknown
- 2009-11-30 ZA ZA2009/08470A patent/ZA200908470B/en unknown
- 2009-11-30 MA MA32388A patent/MA31403B1/fr unknown
- 2009-12-14 CO CO09142782A patent/CO6251322A2/es not_active Application Discontinuation
- 2009-12-14 CO CO09142781A patent/CO6251321A2/es not_active Application Discontinuation
2010
- 2010-01-04 MA MA32475A patent/MA31668B1/fr unknown
- 2010-01-06 CR CR11195A patent/CR11195A/es unknown
- 2010-01-06 CR CR11194A patent/CR11194A/es not_active Application Discontinuation
2011
- 2011-11-17 US US13/299,030 patent/US20120134982A1/en not_active Abandoned
2015
- 2015-10-06 CY CY20151100886T patent/CY1116762T1/el unknown

Also Published As

Publication number	Publication date
MX2009013138A (es)	2010-04-30
EA201100546A1 (ru)	2011-12-30
US20120134982A1 (en)	2012-05-31
EA200901494A1 (ru)	2010-06-30
EA018723B1 (ru)	2013-10-30
HK1138022A1 (en)	2010-08-13
CA2688433A1 (en)	2008-12-11
DK2162467T3 (en)	2015-08-24
EP2746290B1 (en)	2019-08-14
CL2008001674A1 (es)	2008-11-21
HUE025899T2 (en)	2016-05-30
WO2008149150A3 (en)	2009-06-25
TW200918088A (en)	2009-05-01
AR066850A1 (es)	2009-09-16
WO2008149149A2 (en)	2008-12-11
AR066847A1 (es)	2009-09-16
CN104311663B (zh)	2018-11-02
KR20100041746A (ko)	2010-04-22
AU2008259515A1 (en)	2008-12-11
BRPI0812795C1 (pt)	2021-05-25
TW200911831A (en)	2009-03-16
US20090148437A1 (en)	2009-06-11
CO6251321A2 (es)	2011-02-21
DOP2009000268A (es)	2010-02-28
PT2162467E (pt)	2015-10-29
PL2162467T3 (pl)	2015-12-31
AU2008259514A1 (en)	2008-12-11
MX2009012967A (es)	2010-04-01
BRPI0812268A2 (pt)	2019-09-10
TW200902551A (en)	2009-01-16
CA2688447C (en)	2016-11-08
KR20100018040A (ko)	2010-02-16
JP5444215B2 (ja)	2014-03-19
PE20090322A1 (es)	2009-04-20
PE20090763A1 (es)	2009-07-10
SI2162467T1 (sl)	2015-11-30
AU2008259514B2 (en)	2014-05-15
MA31668B1 (fr)	2010-09-01
CA2688434A1 (en)	2008-12-11
EP2162468A2 (en)	2010-03-17
KR20100040841A (ko)	2010-04-21
JP2010530220A (ja)	2010-09-09
US20100247515A1 (en)	2010-09-30
EP2746291A2 (en)	2014-06-25
AU2008259590A1 (en)	2008-12-11
US20100266616A1 (en)	2010-10-21
CR11195A (es)	2010-05-24
SG182141A1 (en)	2012-07-30
EP2746290A2 (en)	2014-06-25
EP2162467A2 (en)	2010-03-17
IL202204A0 (en)	2010-06-16
CO6251322A2 (es)	2011-02-21
HRP20151024T1 (hr)	2015-11-06
IL201398A0 (en)	2010-05-31
CN101778865B (zh)	2016-11-09
JP5325211B2 (ja)	2013-10-23
BRPI0812795B8 (pt)	2020-01-28
MX2009013137A (es)	2010-04-30
AR066848A1 (es)	2009-09-16
ZA200908470B (en)	2011-02-23
BRPI0813899A2 (pt)	2019-09-24
EA200901495A1 (ru)	2010-10-29
MA31403B1 (fr)	2010-05-03
CY1116762T1 (el)	2017-03-15
SG182151A1 (en)	2012-07-30
TW200907128A (en)	2009-02-16
KR101604274B1 (ko)	2016-03-17
EP2164867A2 (en)	2010-03-24
US20110256122A1 (en)	2011-10-20
WO2008149149A3 (en)	2009-04-02
US8398979B2 (en)	2013-03-19
PE20090323A1 (es)	2009-04-20
CA2688447A1 (en)	2008-12-11
TW200911834A (en)	2009-03-16
CA2683791A1 (en)	2008-12-11
NZ581372A (en)	2012-02-24
CN104311663A (zh)	2015-01-28
EP2746291B1 (en)	2019-08-14
EP2162467B1 (en)	2015-07-22
JP2010530364A (ja)	2010-09-09
EA200901491A1 (ru)	2010-08-30
MX2009013211A (es)	2010-04-09
JP2010529841A (ja)	2010-09-02
ES2546943T3 (es)	2015-09-30
CR11194A (es)	2010-06-28
EP2746291A3 (en)	2014-09-03
CA2683823A1 (en)	2008-12-11
EA018129B1 (ru)	2013-05-30
CL2008001676A1 (es)	2008-11-21
BRPI0812795B1 (pt)	2019-12-03
TW200911832A (en)	2009-03-16
CN101802004A (zh)	2010-08-11
WO2008149148A2 (en)	2008-12-11
CA2688456A1 (en)	2008-12-11
CN101883788A (zh)	2010-11-10
WO2008149148A3 (en)	2009-04-02
AU2008259516A1 (en)	2008-12-11
CN101778865A (zh)	2010-07-14
EP2746290A3 (en)	2014-09-10
KR20100021642A (ko)	2010-02-25
CL2008001673A1 (es)	2008-11-21
WO2008149150A2 (en)	2008-12-11
EA200901300A1 (ru)	2010-06-30

Publication	Publication Date	Title
BRPI0812795A2 (pt)	2014-12-02	Domínio variável único de imunoglobulina, antagonista tipo 1 do receptor tnfalfa, uso do antagonista de tnfr1, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, composição farmacêutica, polipeptídeo, e, proteína de fusão.
WO2007122591A3 (en)	2008-01-10	Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
LTPA2018017I1 (lt)	2019-01-10	Žmogaus CGRP receptorių rišantys antikūnai
DK1933871T3 (da)	2013-07-08	Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1
EP2184981A4 (en)	2012-02-01	PYRIDINE carboxamide-orexin receptor Antagonist
EP2214676A4 (en)	2011-08-03	SUBSTITUTED DIAZEPANES AS ANTAGONISTS OF OREXIN RECEPTORS
DK2197900T3 (da)	2012-10-22	Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
DE602004020610D1 (de)	2009-05-28	Neue, an den erythropoietinrezeptor bindende peptide
WO2009068649A3 (en)	2010-02-04	Antigen-binding constructs
EP1981902A4 (en)	2009-12-23	ANTAGONISTS OF NOGO RECEPTORS
MX2009008104A (es)	2009-08-07	Hepcidina, antagonistas de hepcidina y metodos de uso.
DK1720859T3 (da)	2010-04-26	Chemokinreceptorantagonister
DE602004030930D1 (de)	2011-02-17	Muscarinische acetylcholin-rezeptor-antagonisten
BRPI0821784A2 (pt)	2015-09-29	receptor de navegação
IL204536A0 (en)	2010-11-30	Anti - il -6 receptor antibody
BRPI0813016A2 (pt)	2015-12-15	"proteínas de ligação de antígeno ao receptor de il-18"
EP1933702A4 (en)	2011-12-07	LEAD SERIES
DK1625156T3 (da)	2013-01-07	Peptider, der bindes til erythropoietinreceptoren
EP2349269A4 (en)	2012-04-25	2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
EP1786463A4 (en)	2009-05-20	ANTIBODY AGAINST NOGO RECEPTOR
IL201865A0 (en)	2011-08-01	Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof
BRPI0720976A2 (pt)	2015-06-16	Barreira de tráfego alongada rebocável, e barreira de tráfego alongada
BRPI0811551A2 (pt)	2014-12-09	Articulação de quatro pontos
BRPI0920979A2 (pt)	2016-01-05	composições de minerais de asfalto.
ZA201103588B (en)	2012-01-25	Polypeptides,antibody variable domains & antagonists

Legal Events

Date	Code	Title	Description
2017-03-28	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-10-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-06-12	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-06-26	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-03-06	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-05	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-12-03	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS
2020-01-14	B09W	Correction of the decision to grant [chapter 9.1.4 patent gazette]	Free format text: RETIFICA A PUBLICACAO 9.1 DA RPI NO 2548 (05/11/2019) POR TER SIDO EFETUADA COM INCORRECOES.
2020-01-28	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REFERENTE A RPI 2552 DE 03/12/2019, QUANTO AO RELATORIO DESCRITIVO.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-04-04	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 15A ANUIDADE.
2023-07-25	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.